OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
Careful selection is essential for achieving viscosity reduction without protein destabilization.
Regenerative medicines boast a rich clinical pipeline.
New technologies and treatments are emerging—along with new variants.
April 26, 2022
Johnson & Johnson has launched its next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town.
April 21, 2022
The European Investment Bank has provided €15 million to fund coronavirus research at IRBM.
April 20, 2022
Otsuka Pharmaceutical and Osaka University have entered an exclusive license agreement on a new anti-tumor antibody.
April 18, 2022
AmoyDX has entered a Master Collaboration Agreement with AstraZeneca for multiple companion diagnostics programs in China, EU, and Japan.
April 14, 2022
ReiThera and Exothera are collaborating to develop a large-scale, low-cost-per-dose manufacturing process to deliver novel vaccines to low and middle-income countries.
April 13, 2022
Battles against antibiotic-resistant bacteria can be won with bacteriophages.
With high-concentration biologics, careful selection of excipients in formulation is crucial for reducing viscosity without destabilizing the protein.
April 12, 2022
Opus enters a strategic collaboration with Resilience for AAV-based gene therapy development and manufacturing for inherited retinal diseases.
April 11, 2022
IAVI and Moderna have announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health issues.
April 08, 2022
Evonetix’s thermally controlled DNA synthesis technology is designed to enable highly parallel DNA synthesis in a benchtop platform.